According to Savara Pharmaceuticals, the company has created a Clinical Advisory Board to provide advice on the development of AeroVanc vancomycin hydrochloride inhalation powder for the treatment of MRSA lung infections in patients with cystic fibrosis. The five members of the new board are: Michael P. Boyle, Associate Professor of Medicine and Director of the … [Read more...] about Savara announces clinical advisory board
Medical
Critical reports positive results for intranasal growth hormone study
According to Critical Pharmaceuticals, a Phase 1b study has shown that its CP024 dry powder intranasal human growth hormone (hGH) was well tolerated with only a few minor adverse effects and showed a linear dose response. CP024 also induced production of therapeutic levels of insulin-like growth factor (IGF-1), making it the first nasal formulation of growth hormone … [Read more...] about Critical reports positive results for intranasal growth hormone study
NEONC announces planned trial of intranasal therapy for brain cancer
California-based NEONC Technologies has announced plans for clinical trials of its NEO100 intranasal formulation of monoterpene perillyl alcohol (POH) for the treatment of gliomas and other CNS cancers. NEONC Chairman and CEO Thomas Chen, who is also Co-Director of the USC/Norris Neuro-Oncology Program and Professor of Neurological Surgery and Pathology at USC's Keck … [Read more...] about NEONC announces planned trial of intranasal therapy for brain cancer
NICE recommends TOBI Podhaler and Colobreathe for CF patients
The UK's National Institute for Health and Clinical Excellence (NICE) has issued a qualified recommendation for Forest Lab's Colobreath colistimethate sodium and Novartis's TOBI Podhaler tobramycin dry powders for inhalation as options for the treatment of P. aeruginosa lung infections in patients with cystic fibrosis. The recommendation is a final draft; the final … [Read more...] about NICE recommends TOBI Podhaler and Colobreathe for CF patients
Fast food consumption linked to severity of asthma, rhinitis in children
An article posted online in Thorax on January 14, 2013 finds that children and teens who eat three or more servings of fast food per week have a significantly increased risk of severe asthma. The same fast food intake was also associated with increased risk of eczema and rhinitis, while fruit consumption was found to have an inverse association with severe asthma and … [Read more...] about Fast food consumption linked to severity of asthma, rhinitis in children
Teva Pro-Air MDI with dose counter now available in US
Teva Respiratory says that the ProAir HFA metered dose inhaler with dose counter for the treatment of asthma is now available. The albuterol MDI with dose counter was approved by the FDA in March 2012. At the time, the company announced that the new inhaler would be available by the end of 2012. Teva says that it needed time to manufacture a sufficient inventory to … [Read more...] about Teva Pro-Air MDI with dose counter now available in US
Matrixx Initiatives recalls single lot of Zicam nasal spray
Matrixx Initiatives has voluntarily recalled a single lot of Zicam Extreme Congestion Relief nasal gel spray due to contamination with Burkholderia cepacia in a single sample. Zicam is a homeopathic product available over the counter in the US. The affected lot, which was distributed to retailers throughout the US, is number 2J23. The 0.5 oz spray bottles are … [Read more...] about Matrixx Initiatives recalls single lot of Zicam nasal spray
Theravance initiates Phase 2b study of investigational LAMA
Theravance has begun a dose ranging Phase 2b study of its TD-4208 inhalation solution in approximately 60 patients with moderate to severe COPD. According to the company, "The goal of Theravance's LAMA program for respiratory disease is to develop a once-daily inhaled medicine in a nebulizer that offers improved efficacy and tolerability relative to current therapies … [Read more...] about Theravance initiates Phase 2b study of investigational LAMA
Study shows Aradigm’s Lipoquin protects against plague in mice
A study by scientists from the UK Defence Science and Technology Laboratory (Dstl) showed that a single dose of Aradigm's Lipoquin liposomal ciprofloxacin administered through the nose fully protected mice exposed to an aerosolized "lethal dose" of Yersinia pestis. Inhaled aerosolized Lipoquin provided 70% protection, while untreated mice and those given a single dose … [Read more...] about Study shows Aradigm’s Lipoquin protects against plague in mice
OptiNose announces Phase 3 data, grant
OptiNose has announced Phase 3 results from a study of its sumatriptan nasal powder for the treatment of migraine, as well as a grant from the Research Council of Norway to study nasal delivery of oxytocin for the treatment of autism spectrum disorders. According to OptiNose US, the Phase 3 TARGET study found that 42% of patients with moderate to severe migraines … [Read more...] about OptiNose announces Phase 3 data, grant